IMV News and Press, IMV Inc. From 01/03/23

Announces Special Dividend and $50 Million Stock Repurchase Program Focus on driving multi-year step function increase in valuation Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today reported management changes, a special ca...

IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX ® , to potentially treat solid and hematologic cancers, announ...

IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based on the Company’s immune-educating platform, DPX ® , to potentially treat solid and hematologic cancers, announ...

Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors Oral presentation ...

Immersion Corporation (NASDAQ: IMMR), a leading developer and provider of technologies for haptics, today announced that it renewed a multi-year license with Dongwoon Anatech, which creates analog integrated circuits (ICs) for phones, wearables, and other electronic devices, to make Immersion hap...

IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, announced that its common shares...

Biopharmaceutical company IMV ( NASDAQ: IMV ) ( TSX: IMV:CA ) to effect a 1-for-10 reverse stock split, having said its shareholders have approved the consolidation plan with 87.87% votes. The board approved a 1-for-10 reverse stock split of the company's shares immediately af...

IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX&...

IMV Inc. (“ IMV ” or the “ Company ”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX ® platform to treat solid and hematologic cancers, today announced that, on No...

IMV, Inc. (IMV) Q3 2022 Earnings Conference Call November 11, 2022 08:00 AM ET Company Participants Brittany Davison - Chief Accounting Officer Andrew Hall - Chief Executive Officer Jeremy Graff - Chief Scientific Officer Conference Call Participants ...